3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
56
Leukemia
52
Lymphoma
37
Myelodysplastic Syndromes
26
Precursor Cell Lymphoblastic Leukemia-Lymphoma
23
Lymphoma, Non-Hodgkin
22
Hodgkin Disease
22
Leukemia, Myeloid, Acute
18
Multiple Myeloma
17
Myeloproliferative Disorders
14
Recurrence
12
Lymphoma, Mantle-Cell
12
Lymphoma, Large B-Cell, Diffuse
11
Lymphoma, T-Cell, Peripheral
10
Lymphoma, Follicular
10
Congenital Abnormalities
10
Neoplasms, Plasma Cell
9
Lymphoma, B-Cell, Marginal Zone
9
Leukemia, Myeloid, Chronic-Phase
9
Hematologic Neoplasms
9
Burkitt Lymphoma
9
Anemia, Aplastic
9
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Waldenstrom Macroglobulinemia
7
Myelodysplastic-Myeloproliferative Diseases
7
Lymphoma, T-Cell
7
Lymphoma, Large-Cell, Immunoblastic
7
Graft vs Host Disease
7
Sezary Syndrome
6
Primary Myelofibrosis
6
Interventions
Cyclophosphamide
3
fludarabine phosphate
2
fludarabine
2
AP 1903 reagent
2
thymoglobulin
1
ruxolitinib
1
Whole-Body Irradiation
1
Tacrolimus
1
Rituximab
1
Peripheral Blood Stem Cell Transplantation
1
Panobinostat
1
Mycophenolic Acid
1
Mesna
1
Dexamethasone
1
Busulfan
1
Bortezomib
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Thalassemia
×
Alemtuzumab
×
Clear all
NCT00578292
2020-05-01
THALLO
Baylor College of Medicine
Phase NA
Terminated
10 enrolled
15 charts